Tous Actualités
Suivre
Abonner Intercell AG

Intercell AG

Intercell´s clinical data on Japanese Encephalitis vaccine published in "The Lancet"

Wien (euro adhoc) -

Intercell´s (ICLL) Phase III clinical trial results on its 
investigational Japanese Encephalitis vaccine have been published in 
the renowned medical journal “The Lancet” The article is the first 
publication describing the full clinical data to date on Intercell´s 
vaccine against Japanese Encephalitis The publication details 
significant safety and immunogenicity results on the ICLL vaccine, 
which represents an innovative approach against a disease with a high
degree of unmet medical need
  ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for
  the content of this announcement.
research
Vienna (Austria), December 3, 2007 - Intercell
(VSE: ICLL) is pleased to announce the acceptance of a scientific 
article about its investigational Japanese Encephalitis vaccine by 
the internationally-renowned scientific and medical journal "The 
Lancet".
With over 3 billion people living in endemic areas, Japanese 
Encephalitis, a mosquito-borne flaviviral infection, is the leading 
cause of childhood encephalitis and viral encephalitis in Asia. 
Japanese Encephalitis represents a clear threat to travellers and 
military personnel from industrialized countries visiting endemic 
areas. The disease is usually severe, resulting in residual 
neuropsychiatric sequelae in up to 50% of cases and a fatal outcome 
in about 25% of all cases. No treatment is currently available, only 
vaccination effectively prevents the disease. Intercell´s innovative 
investigational vaccine, which is planned to enter global markets in 
2008, is a purified, inactivated product for active immunization 
against viral infections of Japanese Encephalitis.
In a recently concluded Phase III non-inferiority trial, Intercell´s
investigational Japanese Encephalitis vaccine demonstrated
» Immunogenicity against Japanese Encephalitis comparable to that of 
the U.S.   licensed product, JE-VAX®
» An overall clinical safety profile similar to placebo combined with
an   excellent local tolerability profile
Intercell´s innovative investigational vaccine, which is manufactured
in the company´s proprietary manufacturing facility in Scotland, is 
prepared using tissue culture rather than live organisms and does not
contain stabilizers such as gelatin or preservatives in its 
formulation.
The article published in "The Lancet" reports of the detailed 
findings in a multicenter, multinational, observer-blinded randomized
controlled Phase III non-inferiority study. The paper was written 
under the lead of Intercell´s Vice President of Clinical Development 
& Medical Officer, Dr. Erich Tauber, in cooperation with scientists 
from the Medical University of Vienna, Austria and University of 
Washington, Seattle, USA as well as the Medical University Innsbruck,
Austria.
"This publication on our vaccine means that Intercell´s approach and 
the data of our study have been peer-reviewed by highly-ranked 
independent scientific and medical experts, who came to the 
conclusion that our innovative vaccine, if approved, will meet a 
major medical need," stated Alexander von Gabain, Chief Scientific 
Officer of Intercell AG. He added: "It is a valuable appreciation of 
our scientific work that our data has been published in The Lancet, 
which is one of the world´s leading medical journals."
"The Lancet", which first appeared in the year 1823, is an 
independent and authoritative voice in global medicine that seeks to 
publish high-quality clinical trials that will alter medical 
practice. "The Lancet" delivers in-depth knowledge in key medical 
disciplines. (www.thelancet.com)
end of announcement                               euro adhoc 03.12.2007 08:35:00

Further inquiry note:

Intercell AG
Lucia Malfent
Head of Communications
Tel. +43 1 20620-303
lmalfent@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Börsen: Wiener Börse AG / official market

Plus de actualités: Intercell AG
Plus de actualités: Intercell AG